热门资讯> 正文
Deliverx将在旧金山举行的AANEM年会和MGFA科学会议上展示VYVGART和Empasiprubart数据
2025-10-15 13:11
- Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patients
- Real-world evidence and long-term data reinforce VYVGART's sustained impact on patient outcomes
- More than 40 abstracts across MG, CIDP, MMN, and IIM highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。